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Abstract: This is an analysis from a chemical point of view of the 22 drugs accepted by the FDA
during 2016. The different drugs from the 2016 “harvest” have been classified according to their
chemical structure: antibodies; TIDES (oligonucleotides and peptides); amino acids and natural
products; drug combination; and small molecules.
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Health is possibly one of the most “magical” words associated with the development of the
human being. From the most ancient societies to the present, restoring or improving social health
and wellbeing has been a major pursuit. Although the use of traditional medicines, based mainly
on the use of natural products treated with simple manipulations, continues to be common in some
communities worldwide for the treatment of some diseases, the last century witnessed the birth of the
pharmaceutical industry [1].
The pharmaceutical sector is, without a doubt, the most intriguing industrial activity. At a glance,
it is associated with heavy investments, strong regulations, and a low number of outputs in terms of
new products [2]. During the last 20 years (1997–2016), the U.S. Food and Drug Administration (FDA),
which is probably the most important regulatory agency, followed by the European Medicines Agency
(EMA), has approved a total of 595 new entities [3,4]. Of these, 491 were new chemical entities (NCEs)
and 103 biologics, the latter accounting for 17% of the total (Figure 1). The pharmaceutical industry
produces approximately 30 new entities yearly—25 being NCEs and five biologicals.
With this relatively low number of new products in the market, an analysis of the new entities
approved by the FDA performed at the end of the year can reflect the “health” of the sector.
In 2016, a total of 22 new entities were approved by the FDA—of these 15 NCEs and
seven biologicals. These figures caused some surprise among analysts [4,5], because in 2015 and
2014 the same agency approved 45 (33 + 12) and 41 (30 + 11), respectively. These last figures were the
first and third best in the two decades. Analysts interpret these numbers with caution, because it is
important to take into account that launching a new drug into the market is slow process that can take
an average of between 10 and 15 years. Therefore delays in drugs reaching the market can result from
the intrinsic dynamics of the process itself and from associated players such as GMP manufacturers,
because it should be born in mind that the production of many of the new drugs is highly challenging.
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Figure 1. New Chemical Entities and Biologics approved by the FDA in the last two decades [3,4]. 
On the basis of the analysis of FDA figures in 2016, it can be concluded that the niche occupied 
by biologics (seven monoclonal antibodies) is growing. In this regard, 2016 (Table 1) was the third 
best year after 2015 (12) and 2014 (11), with biologics accounting for 32% of the total for the year, which is 
the highest figure in two decades. Investments in this field are increasing. In this regard, the development 
of antibody drug conjugates (ADCs) and proteins ensures an increase in biologics production.  
Table 1. Monoclonal Antibodies approved by the FDA during 2016 a. 
Trade Name Active Ingredient Target/Disease 
Anthim Obiltoxaximab Anthrax 
Cinqair Reslizumab Severe asthma 
Lartruvo Olaratumab Soft tissue sarcoma 
Taltz Ixekizumab Plaque psoriasis 
Tecentriq Atezolizumab Urothelial carcinoma 
Zinbryta Daclizumab Multiple sclerosis 
Zinplava Bezlotoxumab C. difficile recurrence 
a Source FDA. 
An analysis of the FDA data on NCEs (which until just a few years ago were primarily small 
molecules) for 2016 reveals that three oligonucleotides were approved (Figure 2). Thus, the approval  
of Spinraza, a 18-mer antisense oligonucleotide targeting spinal muscular atrophy (Figure 2B);  
Exondis 51, a 30-mer morpholino phosphorodiamidate antisense oligomer against Duchenne muscular 
dystrophy (Figure 2C); and Defitelio, a mixture of oligodeoxyribonucleic acids for hepatic veno-occlusive 
disease (Figure 2D), marks the advancement of these chemical species and implies a returns on the 
large investments made by the pharmaceutical industry in this field since the earlier 1990s. 
Figure 1. New Chemical Entities and Biologics approved by the FDA in the last two decades [3,4].
On the basis of the analysis of FDA figures in 2016, it can be concluded th t the niche occupied by
biologics (seven monoclonal antibodies) is growing. In this regard, 2016 (Table 1) was the third best
year after 2015 (12) and 2014 (11), with biologics accounting for 32% of the total for the year, which is the
highest figure in two decades. Investments in this field are increasing. In this regard, the development
of antibody drug conjugates (ADCs) and proteins ensures an increase in biologics production.
Table 1. Monoclonal Antibodies approved by the FDA during 2016 a.
Trade Name Active Ingredient Target/Disease
Anthim Obiltoxaximab Anthrax
Cinqair Reslizumab Severe asthma
Lartruvo Olaratumab Soft tissue sarcoma
Taltz Ixekizumab Plaque psoriasis
Tecentriq Atez lizumab Urothelial carcinoma
Zinbryta Daclizumab Multiple sclerosis
Zinplava Bezlotoxumab C. difficile recurrence
a Source FDA.
An analysis of the FDA data on NCEs (which until just a few years ago were primarily small
molecules) for 2016 reveals that three oligonucleotides were approved (Figure 2). Thus, the approval
of Spinraza, a 18-mer antisense oligonucleotide targeting spinal muscular atrophy (Figure 2B);
Exondis 51, a 30-mer morpholino phosphorodiamidate antisense oligomer against Duchenne muscular
dystrophy (Figure 2C); and Defitelio, a mixture of oligodeoxyribonucleic acids for hepatic veno-occlusive
disease (Figure 2D), marks the advancement of these chemical species and implies a returns on the
large investments made by the pharmaceutical industry in this field since the earlier 1990s.
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Figure 2. General structure of oligonucleotide-based drugs. Standard RNA strand (A); Phosphorothioate 
backbone (B); Morpholino Phosphorodiamidate backbone (C); Standard DNA strand (D). 
Other TIDES (oligo- pep-TIDES) approved this year include Adlyxin, a 44-amino acid peptide 
antidiabetic (Figure 3), with a molecular weight of 4858 that belongs to the family of glucagon-like 
peptide-1 (GLP-1) agonist. Specifically, Adlyxin is derived from exendin-4, where the Pro at the  
C-terminal has been removed and a linker of Lys6 (Figure 3, highlighted Blue) has been added  
instead [6]. 
 
Figure 3. Structure of Adlyxin. 
These four biomolecules are a clear example of the power of solid-phase synthesis for the 
industrial production of TIDES-based Active Pharmaceutical Ingredients (APIs). Only a few years 
ago, the pharmaceutical industry was reluctant to consider peptides and oligonucleotides of this size 
as potential drugs, because of the lack of reliable chemical strategies for their preparation. However, 
the synthetic advances using the solid-phase methodology now makes the production of these large 
TIDES-based APIs feasible.  
From a chemical point of view, it is interesting to highlight Xiidra (for dry eye disease), because it 
is a acyl dipeptide formed by two unnatural amino acids, 3-methylsulfonylphenylalanine (Figure 4A, 
blue) and 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (Figure 4A, orange), whose 
amine is acylated with benzenebenzofuran-6-carboxylic acid. 
Briviact (epilepsy) is a compound derived from the amino acid α-ethylglycinamide (Figure 4B, 
blue). Continuing with amino acids, Alumni is an α,α-disubstitutedglycine (Figure 4C, blue) bearing 
an 18F atom and used as a diagnostic agent in positron emission tomography (PET) imaging for 
prostate cancer. In this same class, Netspot has been approved as a kit for the preparation of 68Ga 
dotatate injection for PET scans. In the field of natural product-based drugs, Ocaliva (primary biliary 
cholangitis), which is a semisynthetic bile acid, has been also approved (Figure 4D). 
 
Figure 2. General structure of oligonucleotide-based drugs. Standard RNA strand (A); Phosphorothioate
backbone (B); Morpholino Phosphorodiamidate backbone (C); Standard DNA strand (D).
Other TIDES (oligo- pep-TIDES) approved this year include Adlyxin, a 44-amino acid peptide
antidiabetic (Figure 3), with a molecular weight of 4858 that belongs to the family of glucagon-like
peptide-1 (GLP-1) agonist. Specifically, Adlyxin is derived from exendin-4, where the Pro at the
C-terminal has been removed and a linker of Lys6 (Figure 3, highlighted Blue) has been added
instead [6].
Molecules 2017, 22, 368 3 of 6 
 
 
Figure 2. General structure of oligonucleotide-based drugs. Standard RNA strand (A); Phosphorothioate 
backbone (B); Morpholino Phosphorodiamidate backbone (C); Standard DNA strand (D). 
Other TIDES (oligo- pep-TIDES) approved this year include Adlyxin, a 44-amino acid peptide 
antidiabetic (Figure 3), with a molecular weight of 4858 that belongs to the family of glucagon-like 
peptide-1 (GLP-1) agonist. Specifically, dlyxin is derived fro  exendin-4, here the Pro at the  
C-terminal has been removed and a linker of Lys6 (Figure 3, highlighted Blue) has been added  
instead [6]. 
 
Figure 3. Structure of Adlyxin. 
These four biomolecules are a clear example of the power of solid-phase synthesis for the 
industrial production of TIDES-based Active Pharmaceutical Ingredients (APIs). Only a few years 
ago, the pharmaceutical industry was reluctant to consider peptides and oligonucleotides of this size 
as potential drugs, because of the lack of reliable chemical strategies for their preparation. However, 
the synthetic advances using the solid-phase methodology now makes the production of these large 
TIDES-based APIs feasible.  
From a chemical point of view, it is interesting to highlight Xiidra (for dry eye disease), because it 
is a acyl dipeptide formed by two unnatural amino acids, 3-methylsulfonylphenylalanine (Figure 4A, 
blue) and 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (Figure 4A, orange), whose 
amine is acylated with benzenebenzofuran-6-carboxylic acid. 
Briviact (epilepsy) is a compound derived from the amino acid α-ethylglycinamide (Figure 4B, 
blue). Continuing with amino acids, Alumni is an α,α-disubstitutedglycine (Figure 4C, blue) bearing 
an 18F atom and used as a diagnostic agent in positron emission tomography (PET) imaging for 
prostate cancer. In this same class, Netspot has been approved as a kit for the preparation of 68Ga 
dotatate injection for PET scans. In the field of natural product-based drugs, Ocaliva (primary biliary 
cholangitis), which is a semisynthetic bile acid, has been also approved (Figure 4D). 
 
Figure 3. Structure of Adlyxin.
These four biomolecules are a clear example of the power of solid-phase synthesis for the
industrial production of TIDES-based Active Pharmaceutical Ingredients (APIs). Only a few years
ago, the i stry was reluctan to consider eptides and oligonucleotides of this
size as potential drugs, b cause of the lack of reliable chemical trategies for their preparation.
However, the synthetic advances using the solid-phase methodology now makes the production
of these large TIDES-based APIs feasible.
From a chemical point of view, it s inter sting to highlight Xiidra (for dry e disease), because it is
a acyl dipeptide formed by two unnatur l amino acids, 3-methylsulfonylphenylala ine (Figure 4A, blue)
and 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (Figure 4A, orange), whose amine i
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(Figure 4B, blue). Continuing with amino acids, Alumni is an α,α-disubstitutedglycin (Figure 4C, blue)
bearing an 18F atom and used as a diagnostic agent in p sitron emissi n t mography (PET) ima ing
fo prostate cancer. In thi same class, Netspot has b en approve f r the preparation of 68Ga
dotatate injection for PET scans. In the field of natural product-based drugs, Ocaliva (primary biliary
cholangitis), which is a semisynthetic bile acid, has been also ap roved (Figure 4D).
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Figure 4. Structures of Xiidra (A), Briviact (B); Auxim (C); and Ocaliva (D). 
Zepatier (Figure 5A) and Epclusa (Figure 5B) are two two-drug combinations for the treatment of 
hepatitis C. Both contains a hepatitis C virus NSSA inhibitor (Elbasvir and Velpatasvir, respectively) 
and Grazopevir (macrocycle, NS3/4A protease inhibitor) and Sofosbuvir (nucleotide, viral RNA 
polymerase inhibitor), respectively. 
 
Figure 5. Structures and composition of Zepatier (A) and Epclusa (B). 
 
Figure 4. Structures of Xiidra (A); Briviact (B); Auxim (C); and Ocaliva (D).
Zepatier (Figure 5A) and Epclusa (Figure 5B) are two two-drug combinations for the treatment of
hepatitis C. Both contains a hepatitis C virus NSSA inhibitor (Elbasvir and Velpatasvir, respectively)
and Grazopevir (macrocycle, NS3/4A protease inhibitor) and Sofosbuvir (nucleotide, viral RNA
polymerase inhibitor), respectively.
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The last four compounds: Rubraca an indole derivative for the treatment of patients with
deleterious BRCA mutation associated to ovarian cancer (Figure 6A); Eucrisa, a hemiboronate for
atopic dermatitis (Figure 6B); Nuplazid, which acts in some psychotic disorders in Parkinson’s disease,
and is a trisubstituted urea (Figure 6C); and Venclexta, a complex sulfonamide used in the treatment
of chronic lymphocytic leukaemia (Figure 6D), are those that best fit the small molecule category,
although the last one has a molecular weight of 868.
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In conclusion, while the number of drugs approved by the FDA in 2016 was smaller than expected, 
taking into account preceding years, they show great diversity from a chemical point of view. In this 
regard, the most important highlight is probably the presence of the three oligonucleotides, which are 
expected to open up new avenues for this key category of biomolecule. Advances in the solid-phase 
methodology for the preparation of large TIDES are driving the development of these kinds of 
biomolecule as APIs [7]. The approval of seven monoclonal antibodies is also worth noting. There is 
no doubt that this class of biologics is the most suitable for the treatment of hitherto intractable 
diseases. More ADCs are expected to be approved in the coming years, thus positioning antibodies 
as first class pharmaceuticals. The outputs from 2016 indicate the so-called small molecules are losing 
ground against biologics, biomolecules, and other molecules inspired on natural products. However, 
the ultimate aim of any drug, regardless of the chemical species, is to bring relief to those suffering. 
If this is achieved, many will benefit. 
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In conclusion, while the number of drugs approved by the FDA in 2016 was smaller than
expected, taking into account preceding years, they show great diversity from a chemical point of view.
In this regard, the most important highlight is probably the presence of the three oligonucleotides,
which are expected to open up new avenues for this key category of biomolecule. Advances in
the solid-phase methodology for the preparation of large TIDES are driving the development of
these kinds of biomolecule as APIs [7]. The approval of seven monoclonal antibodies is also
worth noting. There is no doubt that this class of biologics is the most suitable for the treatment
of hitherto intractable diseases. More ADCs are expected to be approved in the coming years,
thus positioning antibodies as first class pharmaceuticals. The outputs from 2016 indicate the so-called
small molecules are losing ground against biologics, biomolecules, and other molecules inspired on
natural products. However, the ultimate aim of any drug, regardless of the chemical species, is to
bring relief to those suffering. If this is achieved, many will benefit.
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